Dabigatran: Is there a role for coagulation assays in guiding therapy?;Dabigatran: ¿tienen las pruebas de coagulación algún papel en guiar la terapia?

Annals of Pharmacotherapy

Volumn 47, Issue 6, 2013, Pages 828-840

  Brunetti, Luigi ^a   Bandali, Farooq ^b  

^a RUTGERS UNIVERSITY   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; DABIGATRAN ETEXILATE; ECARIN; ENOXAPARIN; PHYTOMENADIONE; THROMBIN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COAGULATION ASSAY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT; MEDICAL INFORMATION; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK FACTOR; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84881221868     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R720     Document Type: Article

References (100)

1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:7S-47S. doi: 10.1378/chest.1412S3
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.doi: 10.1056/NEJMoa0905561
3. Product information. Pradaxa (dabigatran etexilate mesylate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., December 2012.
4. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-295. doi: 10.2165/00003088-200847050-00001
5. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacody-namics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(suppl 1):9S-16S.doi: 10.1177/1076029609343004
6. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-563. doi: 10.1177/0091270005274550
7. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacoki-netics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. doi: 10.1111/j.1365-2125.2007.02899.x
8. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabiga-tran, in humans. Drug Metab Dispos 2008;36:386-399.doi: 10.1124/dmd.107.019083
9. Chin PK, Vella-Brincat JW, Barclay ML, Begg EJ. Perspective on dabi- gatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol 2012;74:734-740. doi: 10.1111/j.1365-2125.2012.04266.x
10. VanRyn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-1127. doi: 10.1160/TH09-11-0758
11. VanRyn J, Litzenberger T, Waterman A, et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 2011;57:E1130.
12. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-956. doi: 10.1016/S0140-6736(07)61445-7
13. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-2352. doi: 10.1056/NEJMoa0906598
14. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9. doi: 10.1016/j.arth.2008.01.132
15. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NO-VATE II): a randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721-729. doi: 10.1160/TH10-10-0679
16. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-2185. doi: 10.1111/j.1538-7836.2007.02748.x
17. Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol 2012;50:571-573. doi: 10.3109/15563650.2012.705290
18. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-866. doi: 10.1056/NEJMc1112874
19. QuarterWatch (first quarter 2011). Signals for dabigatran and metoclo-pramide. ISMP medication safety alert, 17(1), January 12, 2012.
20. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-1286. doi: 10.1001/archinternmed.2011.314
21. Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med 2012;157:66-68. doi: 10.7326/0003-4819-157-1-201207030-00467
22. Bene J, Said W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother 2012;46:e14. doi: 10.1345/aph.1Q705
23. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-635. doi: 10.1056/NEJMoa1105594
24. Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis 2010;17:420-427. doi: 10.1053/j.ackd.2010.06.002
25. Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging 2009;4:165-177.
26. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etex-ilate: an open-label, parallel-group, single-centre study. Clin Pharma-cokinet 2010;49:259-268. doi: 10.2165/11318170-000000000-00000
27. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (Re-LY) trial. Circulation 2011;123: 2363-2372. doi: 10.1161/CIRCULATIONAHA.110.004747
28. Prescribing information. Pradaxa (dabigatran etexilate). European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf (accessed 2012 Oct 1).
29. Prescribing information. Pradaxa (dabigatran etexilate). Health Canada. http://www.boehringer-ingelheim.ca/en/Home/Human_Health/Our_Prod-ucts/Product_Monographs/Pradax-pm.pdf (accessed 2012 Oct 1)
30. Kowey PR, Naccarelli G V. The food and drug administration decision not to approve the 110 mg dose of dabigatran: Give us a way out. Am J Med 2012;125:732. doi: 10.1016/j.amjmed.2011.10.035
31. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011;127:457-465. doi: 10.1016/j.thromres.2011.01.001
32. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011;43:682-692. doi: 10.1097/PAT.0b013e32834bf5f4
33. Pare G, Erikkson N, Lehr T. RELY genetics: genetic determinants of dabigatran plasma levels and their relation to clinical response. Presented at: European Society of Cardiology Congress; Munich, Germany; 2012.
34. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharma-codynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59. doi: 10.2165/00003088-200847010-00005
35. Stangier J, Feuring M. Using the Hemoclot direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fib-rinolysis 2012;23:138-143. doi: 10.1097/MBC.0b013e32834f1b0c
36. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexi-late. Thromb Haemost 2012;107:985-997. doi: 10.1160/TH11-11-0804
37. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012;137:572-574. doi: 10.1309/AJCPAU7OQM0SRPZQ
38. Lehr T, Haertter S, Liesenfeld KH, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2011;52: 1373-1378. doi: 10.1177/0091270011417716
39. Duffull SB, Wright DF, Al-Sallami HS, Zufferey PJ, Faed JM. Dabiga-tran: rational dose individualisation and monitoring guidance is needed. N Z Med J 2012;125:148-154.
40. Ten CH. Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 2012;107:803-805. doi: 10.1160/TH12-03-0130
41. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49:761-772. doi: 10.1515/CCLM.2011.134
42. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-847. doi: 10.1160/TH11-10-0718
43. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonval -vular atrial fibrillation (PETRO study). Am J Cardiol 2007;100:1419-1426. doi: 10.1016/j.amjcard.2007.06.034
44. Van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012;125:417-420. doi: 10.1016/j.amjmed.2011.10.017
45. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003;33:173-183. doi: 10.1159/000081505
46. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct throm-bin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-378. doi: 10.1160/TH10-06-0342
47. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007;82:864-873. doi: 10.4065/82.7.864
48. DeRemer CE, Gujral JS, Thornton JW, Sorrentino RA. Dabigatran falsely elevates point of care international normalized ratio results. Am J Med 2011;124:e5-6. doi: 10.1016/j.amjmed.2011.02.009
49. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associat-ed bleeding: case report and review of the literature. J Pharm Pract 2012. Nov 16. (epub ahead of print)
50. US Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate; deputy office director decisional memo application 22-512. October 19, 2010. http://www.Accessdata.Fda.Gov/drugsatfda_docs/nda/2010/022512orig1s000sumr.pdf (accessed 2012 Nov 1).
51. Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran, a direct thrombin inhibitor, in human plasma. J Pharm Biomed Anal 2012;58:152-156.doi: 10.1016/j.jpba.2011.09.018
52. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 2010;16:3436-3441. doi: 10.2174/138161210793563338
53. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012;126:2428-2432. doi: 10.1161/CIRCULATIONAHA.112.123224
54. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012;126:343-348.doi: 10.1161/CIRCULATIONAHA.111.090464
55. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rfVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172-2174. doi: 10.1182/blood-2011-11-393587
56. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-1450.doi: 10.1161/CIRCULATIONAHA.110.004424
57. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Phar-macother 2012;46:e21. doi: 10.1345/aph.1R081
58. Adams HP Jr., del ZG, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.doi: 10.1161/STROKEAHA.107.181486
59. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart As sociation/American Stroke Association. Stroke 2009;40:2945-2948.doi: 10.1161/STROKEAHA.109.192535
60. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29. doi: 10.1056/NEJMoa0804656
61. Pfeilschifter W, Bohmann F, Baumgarten P, et al. Thrombolysis with re-combinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol 2012;71:624-633. doi: 10.1002/ana.23558
62. Marrone LC, Marrone AC. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis 2012;34: 246-247. doi: 10.1159/000342307
63. Matute MC, Guillan M, Garcia-Caldentey J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011;106:178-179 doi: 10.1160/TH11-01-0042
64. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010;30:533-534. doi:10.1159/000319886
65. Sangha N, El Khoury R, Misra V, Lopez G. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis 2012; 21:917.e5-8. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.003
66. Casado Naranjo I, Portilla-Cuenca JC, Jimenez Caballero PE, Calle Escobar ML, Romero Sevilla RM. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 2011;32: 614-615. doi: 10.1159/000334578
67. Casado-Naranjo I, Portilla-Cuenca JC, Jimenez-Caballero PE. Letter by Casado-Naranjo et al. regarding article, "Using dabigatran in patients with stroke: a practical guide for clinicians." Stroke 2012;43:e45. doi: 10.1161/STROKEAHA.111.648212
68. Moey AW, Koblar SA, Chryssidis S, Robinson M, Jannes J. Endovascu-lar therapy after stroke in a patient treated with dabigatran. Med J Aust 2012;196:469-471.
69. Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012;43: 271-279. doi: 10.1161/STROKEAHA.111.622498
70. Micromedex 2.0 (electronic version). Thomson Reuters (Healthcare), Greenwood Village, CO. http://www.thomsonhc.com (accessed 2012 Oct 6).
71. Hartter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012. doi: 10.1111/j.1365-2125.2012.04218.x
72. Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabiga-tran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2012. doi: 10.1111/j.1365-2125.2012.04453.x
73. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thromboly-sis 2011;31:326-343. doi: 10.1007/s11239-011-0561-1
74. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem 2013;59:353-3562. doi: 10.1373/clinchem.2012.189704
75. Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMEL, SIBIOC and CISMEL. Clin Chem Lab Med 2012. doi: 10.1515/cclm-2012-0327
76. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012;52:119S-1125S. doi:10.1177/0091270011415527
77. Mack DR, Kim JJ. Pharmacokinetic and clinical implications of dabiga-tran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Ann Pharmacother 2012;46:1105-1110.doi: 10.1345/aph.1R057
78. Chen BC, Viny AD, Garlich FM, et al. Hemorrhagic complications asso ciated with dabigatran use. Clin Toxicol 2012;50:854-857.doi: 10.3109/15563650.2012.721888
79. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: a consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106: 868-876. doi: 10.1160/TH11-05-0358
80. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. doi: 10.1053/ajkd.2003.50007
81. Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of elderly. Geriatr Gerontol Int 2006;6:149-158.doi: 10.1111/j.1447-0594.2006.00341.x
82. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Sur vey on Atrial Fibrillation. Chest 2010;137:263-272.doi: 10.1378/chest.09-1584
83. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011;155:137-149.doi: 10.1111/j.1365-2141.2011.08826.x
84. Eriksson BI, Dahl OE, Feuring M, et al. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res 2012;130: 818-820. doi: 10.1016/j.thromres.2012.07.004
85. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002;25:899-904.
86. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007;33:223-233.doi: 10.1016/j.ejvs.2006.10.006
87. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 2012;69:1473-1484. doi: 10.2146/ajhp110725
88. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013;34:489-498b.doi: 10.1093/eurheartj/ehs408
89. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(suppl 1): 141-145. doi: 10.1002/ajh.23202
90. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RELY trial. Stroke 2012;43:1511-1517. doi: 10.1161/STROKEAHA.112.650614
91. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-1579.doi: 10.1161/CIRCULATIONAHA.111.029017
92. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-224. doi: 10.1160/TH12-03-0179
93. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004;10(suppl 2):10-16. doi: 10.1111/j.1365-2516.2004.00935.x
94. Dager W, Roberts A. Reversing dabigatran with FEIBA in a patient with transseptal perforation during cardiac ablation. Crit Care Med 2011;39: 243.
95. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialy-sis. Am J Kidney Dis 2013;61:487-489.doi: 10.1053/j.ajkd.2012.08.047
96. New Zealand Pharmaceutical Management Agency. Guidelines for testing and perioperative management of dabigatran. http://www.Pharmac.Govt. Nz/2011/06/13/dabigatran testing AND perioperative management.pdf (accessed 2013 Jan 25).
97. Van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation (abstract 2316). Blood 2011;118:2316.
98. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2013;35:222-224.doi: 10.1111/ijlh.12005
99. Samama MM, Guinet C, Le Flem L. Do new oral anticoagulants re quire laboratory monitoring? The clinician point of view. Thromb Res 2012;130(suppl 1):88-89. doi: 10.1016/j.thromres.2012.08.286
100. US Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate. Advisory comittee briefing document, August 27, 2010. http://www.Fda.Gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadviso-ry committee/ucm226009.pdf (accessed 2012 Nov 1).